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Introduction
The last decade or so has seen major advances in
two key areas of biomedicine: new genetic tech-
nologies, including genomics, proteomics, tran-
scriptomics, metabolomics and the like; and stem
cell technology. Both are touted as offering much
promise in terms of our understanding of basic bio-
logical process and in the translation of this basic
science into mainstream medical practice. But in
both areas much further research must be done to
realise this promise, and this hinges on the appro-
priate and adequate supply of essential research
tools, particularly human tissue, human cells and
human genetic information, which are referred to
collectively here as human biological material. Tissue
collections, banked cell lines and databases of
genetic information, which will be referred to col-
lectively here as human genetic databanks, are vital
stores of these research tools. The people who sup-
ply the tissue, cells and genetic information to
these databanks (collectively referred to here as
sources) play a pivotal role in the success of this
research endeavour. Hence, its success is, to a large
extent, premised on the trust that sources have in
it. Increasingly, entire populations of sources are
being recruited to provide human genetic material
for databanking; in such circumstances, individual
source trust becomes synonymous with public
trust. 
Whilst it is recognised that the issues associated
with trust in human genetic databanking are com-
plex and multifaceted, this article focuses on the
particular problems associated with trust in the
commercialisation of biomedical research utilising
human biological materials stored in human genet-
ic databanks. Commercial development of new
health care products is a key outcome of the
research endeavour. Hence, there is a need for
human genetic databanks to have adequate and
appropriate intellectual property and access policies
that provide some certainty in the rights and oblig-
ations of all parties involved. It will be argued that
one essential requirement for such policies is that
they should explicitly make provision for benefit
sharing arrangements from two distinct perspec-
tives: general benefit to society at large; and specif-
ic benefit to the sources of the original human bio-
logical material and/or their social groupings.
The nature of human genetic databanks
Many human genetic databanks have been in exis-
tence for long periods of time, having been estab-
lished for non-research purposes, for example as
stores of pathological samples.1 Other genetic data-
banks established for particular research projects
also continue to store collections of human biologi-
cal material. In fact, vast numbers of these collec-
tions of biological material are in storage around
the world.2 It has been estimated that 350 million
tissue specimens are stored in repositories in the US
alone,3 with a further 20 million added each year.4
It is now well recognised that these banks of tissue,
cells and information can have significant value for
research, both now and into the future. 
A number of organisations have been established
with the specific purpose of coordinating storage
and distribution of these stores of biological mater-
ial. A good example is the American Tissue Type
Culture Collection (ATCC), a world-wide repository
for biological material, including micro-organisms,
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1 Jean E McEwen, ‘DNA Sampling and Banking: Practices
and Procedures in the United States’ in Bartha Maria
Knoppers, Claude M Laberge and Marie Hirtle (eds) Human
DNA: Law and Policy International and Comparative
Perspectives (The Hague: Kluwer Law International;
1997) at 414.
2 See, for example, Jon F Merz, ‘On the Intersection of
Privacy, Consent, Commerce and Genetic Research’ in
Bartha Maria Knoppers (ed) Populations and Genetics:
Legal and Socio-Ethical Perspectives (Netherlands:
Koninklijke Brill NV; 2003) at 257-258.
3 Ibid.
4 Karen Birmingham, ‘An Inauspicious Start for the US
National Biospecimen Network’ (2004) 113 Journal of
Clinical Investigation 320.
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cell lines and recombinant DNA materials.5 Some of
the major research organizations around the world
store and make available their tissue via the ATCC.
For example, Johns Hopkins University provides its
Special Collection of Biological Materials for
research purposes via the ATCC catalogue.6 The
Wistar Institute also makes available its Special
Collections of various cancer cell lines and hybrido-
mas in this way.7 In Australia, the Western
Australian Research Tissue Network carries out a
similar function, providing a facility for banking
biological materials in that state.8 To date, its col-
lections of samples primarily relate to various forms
of cancer, including breast, ovarian, prostate, col-
orectal and gastric. The network also has ethical
approval to collect and manage health information
related to its collected materials.
The lack of consistency as to methods of collection
and storage and access policies has also encouraged
the creation of more informal tissue or biospecimen
networks, bringing together organisations that
have pre-existing tissue collections. The aim of
these networks is to standardise policies and proce-
dures for storing and accessing the material rather
than to provide actual storage facilities. In
Australia and New Zealand, for example, the
Australasian Biospecimen Network has been estab-
lished to provide a forum to address technical, legal
and ethical, and managerial issues relevant to
human biospecimen repositories within Australia
and New Zealand. The Network is a non-profit sci-
entific organisation with voluntary membership.9
There is also a growing trend to create new large-
scale population human genetic databanks for use
as research tools in wide ranging research pro-
jects.10 In the UK, for example, the Biobank Project
aims to collect tissue samples from 500,000 partic-
ipants aged between 45 and 69 and to use the genet-
ic information extracted from those samples to
identify links between genetic and environmental
factors in common diseases. It is described as the
world’s biggest resource for the study of the role of
nature and nurture in health and disease.11 
One of the first of the large scale population data-
banks was established in Iceland, and it has gener-
ated a large amount of publicity and academic
debate because of the way it is structured, with a
distinctly commercial make up.12 In 1998 legislation
was passed for the establishment of a nationwide
databank of blood samples and genetic informa-
tion, which is linked to other health and genealog-
ical information. deCODE Genetics, a for-profit
company based in Iceland, has been given an exclu-
sive licence from the Icelandic government to man-
age the databank.13 The company is entitled to use
the databank for its own research and to on-licence
to other researchers. 
CARTaGENE is a project based in Quebec in Canada,
the aim of which is to recruit 50,000 individuals to
provide blood samples and anonymised health
information. It will be under the management of a
non-profit institute.14 The Estonian Genome Project
Foundation is a hybrid between the Biobank and
CARTaGENE models and the DeCode model. The
Foundation is a non-profit organisation that has
been set up under legislation to manage a national
databank of tissue and genetic, health and
genealogical information in that country. In addi-
tion, a for-profit company, EGeen, has been given
the right to sell access and information.15
Aside from the databanks described above and oth-
ers of the same nature that store human tissue and
frequently combine it with personal genetic and
health information,16 there are also increasing
numbers of databases of more generic DNA
5 For further information see: http://www.atcc.org/
(last accessed 25 January 2006).
6 See: http://www.atcc.org/common/specialCollections
/JHU.cfm (last accessed 25 January 2006).
7 At: http://www.atcc.org/common/specialCollections/
wistar.cfm (last accessed 25 January 2006).
8 At: http://www.waimr.uwa.edu.au/etc/page.cfm/
SID/11/PID/64 (last accessed 25 January 2006). 
9 For further information see: http://www.abrn.net/
(last accessed 26 January 2006).
10 Geneviève Cardinal and Mylène Deschênes, ‘Surveying the
Population Biobankers’ in Bartha Maria Knoppers (ed)
Populations and Genetics: Legal and Socio-Ethical
Perspectives (Netherlands: Koninklijke Brill NV; 2003).
11 For further information on the UK Biobank Project,
see: http://www.ukbiobank.ac.uk/ (last accessed 24
January 2006)
12 See, for example, Jane Kaye and Paul Martin, ‘Safeguards
for Research Using Large Scale DNA Collections’ (2000)
321 British Medical Journal 1146; Hilary Rose, The
Commodification of Bioinformation: the Icelandic
Health Sector Database (London: The Wellcome Trust;
2001),
13 Ibid at 1147.
14 At: http://www.cartagene.qc.ca/index2.cfm?lang=1
(last accessed 26 January 2006).
15 At: http://www.egeeninc.com/public/ (last accessed
26 January 2006).
16 For a full list as at 2004 see Hans-E Hagen and Jan
Carlstedt-Duke, ‘Building Global Networks for Human
Diseases: Genes and Populations’ (2004) 10 Nature
Medicine 665.
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sequence information.17 The most comprehensive
and well known is GenBank, the publicly accessible
repository of the sequence information produced by
the Human Genome Project.18 Many proprietary
databases also exist. For example, Celera Genomics,
the company that raced against the Human
Genome Project for completion of the human DNA
sequence, offered access to its sequence database
for a fee.19 In addition to the Human Genome
Project, there are a number of other international
collaborative sequencing ventures, notable exam-
ples of which are the SNP Consortium and the
HapMap Project. Both also make sequence informa-
tion available in publicly accessible databases.20
Ethical considerations
Debate about the appropriate rules for regulating
human genetic databanking is intensifying around
the world as their number, size and scope increas-
es. Consent by a source to the storage and use of
their tissue, cells and genetic information is always
likely to be a paramount ethical concern because of
the acute privacy and discrimination issues raised
by the use of identifiable genetic information. Such
matters have been debated extensively in the acad-
emic and policy literature, and countries around
the world are putting in place procedures to allevi-
ate some of these concerns. For example, the aim of
the HapMap project is to map common patterns of
human genetic variation and to determine linkages
with common diseases like diabetes, cancer and
stroke. The early pilot study involved collection of
samples from four representative populations in
Africa, Japan, China and northern and western
Europe, and hence it was highly ethically sensi-
tive.21 Considerable attention was paid to these eth-
ical sensitivities to ensure that the project had the
ongoing support of the populations involved and
society as a whole.
There are likely to be ongoing ethical problems
relating to the use of materials in databanks that
are already in existence, primarily resulting from
the inadequacy of consent requirements that were
in place at the time that the material was collect-
ed.22 These problems can be alleviated to some
extent by ensuring that the material is properly de-
identified before it is supplied to researchers.
However, it is debatable where any material con-
taining human genetic material can ever be truly
de-identified.23 As there is now better recognition
of the importance of securing proper consent to
store and use material for research purposes, any
research projects using materials from more recent-
ly created databanks are likely to pose less problems
from this perspective.24 Nevertheless, the precise
nature of the requirement for valid consent to un-
specified future research use remains problemat-
ic.25
17 Michael G Tyshenko and William Leiss, ‘Current Trends in
Publicly Available Genetic Databases’ (2005) 11 Health
Informatics Journal 295 at 296.
18 Available at: http://www.ncbi.nlm.nih.gov/ (last
accessed 25 January 2006).
19 However, Arti Rai notes that the availability of the
public data placed a ceiling on what Celera could
charge and ultimately resulted in the company mov-
ing out of databanking and into drug development:
Arti K Rai, ’Open and Collaborative Research: a New
Model for Biomedicine (2004) Duke Law School Legal
Studies Research Paper Series Research Paper No 61 at
26-27.
20 One of the lead funding agencies of both projects, the
Wellcome Trust, describes these ventures as two glob-
al partnerships that are characterising variations in
the human genome. It states that single nucleotide
polymorphisms (‘SNPs’) are changes to single letters
of the DNA code, which occur in about one in every
1000 nucleotides. The SNP Consortium is mapping
these SNPs, whereas the HapMap Project is investigat-
ing the combinations of SNPs that are inherited
together: Wellcome Trust, The SNP Consortium and
the International HapMap Project (2005) at: http://
www.wellcome.ac.uk/doc_WTD003500.html (last acces-
sed 25 January 2006). See also Dave A Chokshi and
Dominic P Kwiatowski, ‘Ethical Challenges of Genomic
Epidemiology in Developing Countries (2005) 1/1
Genomics, Society and Policy 1.
21 For an account as to how these ethical issues were
dealt with see International HapMap Consortium,
‘Integrat-ing Ethics and Science in the International
HapMap Project’ (2004) 5 Nature Reviews Genetics 467.
22 Mary R Anderlik, ‘Commercial Biobanks and Genetic
Research Ethical and Legal Issues’ (2003) 3 American
Journal of Pharmacogenomics 203 at 205.
23 In Australia, the second draft revision to the National
Health and Medical Research Council’s National
Statement on Ethical Conduct in Human Research (as
at January 2006) provides at page 26 that: ‘with
advances in genetic knowledge and data linkage, and
the proliferation of tissue banks of identified materi-
al, human tissue samples may always be regarded as,
in principle, potentially re-identifiable.’ Although
that draft has not yet been approved, it does provide
some indication of new ways of thinking about this
contentious issue of identifiability.
24 See, for example, Lorraine Sheremeta, Population
Biobanking in Canada: Ethical Legal and Social Issues
(Canadian Biotechnology Advisory Committee; 2003) at
8. Available at: http://cbac-cccb.ic.gc.ca/epic/inter-
net/incbac-cccb.nsf/en/ah00482e.html (last acces-sed
30 January 2006).
25 For a critique on the ongoing focus on informed con-
sent and individual rights see Garrath Williams,
‘Bioethics and Large-scale Biobanking: Individualistic
Ethics and Collective Projects’ (2005) 1/2 Genomics,
Society and Policy 50. 
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Alongside this issue of consent to use for research
purposes, there are other equally valid and growing
concerns about the direct commercial use of data-
banked material and the more indirect commercial
use of the results of research that has utilised data-
banked material. These concerns are inextricably
linked to the consent question, because arguably
fully informed consent requires disclosure of both
of these direct and indirect commercial dealings
with human genetic material. 
Although the willingness of sources to continue to
provide their materials is vital for most biomedical
research,26 payment for supply is rarely considered
to be a serious option, because of the long-standing
revulsion that society has about the commodifica-
tion of human biological material. This sentiment
is reflected in a number of official international
bioethics documents. For example, the Council of
Europe’s Convention on Human Rights and Biomedicine
provides in Article 21 that: ‘the human body and its
parts shall not, as such, give rise to financial gain’27
and the Universal Declaration on the Human Genome and
Human Rights similarly states in Article 4 that ‘the
human genome in its natural state shall not give
rise to financial gains’.28
At the same time, there is growing awareness that
private companies could make millions of dollars
from the exploitation of inventions developed using
tissue and information that has been freely donat-
ed. The situation becomes increasingly complex
when the managers of human genetic databanks
and the researchers themselves become involved in
the commercialisation processes. There is ample
evidence of the increasing commercialisation of the
storage and research phases of these endeavours.
Although many databanks are non-commercial in
nature, an increasing number of companies are
establishing themselves in this role, deCODE being
the prime example.29 Researchers and research
institutions are also becoming increasingly
involved in the commercial side of biomedical
research and development. They are some of the
most prolific filers of patents in the areas of gene
and stem cell technology and often have partner-
ships with industry to facilitate commercialisation
of their research.30 
In such situations, where everyone but the source
appears to have a financial interest, it is not diffi-
cult to see why the source may feel somewhat mar-
ginalised, and even exploited.31 Whilst some would
argue that this problem could be solved by paying
sources a fair price for their material,32 this view is
not widely supported. On the contrary, in addition
to the potential for this to impact on the cost of
doing biomedical research, there is concern that it
could lead to coercion of the most vulnerable sectors
of society.33 Lori Andrews and Dorothy Nelkin point
out that there is a widespread view that this process
of turning tissue, cell lines and DNA into commodi-
ties not only violates bodily integrity, exploits pow-
erless people and intrudes on community values but
also distorts research agendas and weakens public
trust in scientists and clinicians.34
26 Because of this, John Harris has made the rather contro-
versial argument that individuals actually have an eth-
ical obligation to participate in such research. See John
Harris, ‘Scientific Research is a Moral Duty’ (2005) 31
Journal of Medical Ethics 242.
27 The Convention was signed by the member states on 4
April 1997.
28 The Declaration was adopted by the General Conference
of UNESCO on 11 November 1997.
29 See, for example, Anderlik, above n22;  Merz, above n2
at 263. It has been suggested that a charitable trust
rather than a private company may be a more appro-
priate governance structure for human genetic data-
banks: see David E Winickoff and Richard N Winikoff,
‘The Charitable Trust as a Model for Genomic
Biobanks’ (2003) 349 New England Journal of Medicine
1180. However, such a model is not problem free: see
Andrea Boggio, ‘Charitable Trusts and Human
Research Genetic Databases: the Way Froward?’ (2005)
1/2 Genomics, Society and Policy 41 and a further
response: David E Winikoff and Larissa B Neumann,
‘Towards a Social Contract for Genomics: Property and
the Public in the ‘Biotriust’ Model’ (2005) 1/3
Genomics, Society and Policy 8.
30 Merz, above n2 at 262.
31 It should be recognised that human genetic databank-
ing, of itself, is not necessarily a profitable enterprise.
Indeed, a survey of databankers across Europe in 1999-
2000 revealed that most such activities are not prof-
itable and need to be subsidised: A Cambon-Thomsen
et al, ‘An Empirical Survey on Biobanking of Human
Genetic Material and Data in Six EU Countries’ in
Bartha Maria Knoppers (ed) Populations and Genetics:
Legal and Socio-Ethical Perspectives (Netherlands:
Koninklijke Brill NV; 2003) 141 at 153.
32 John C Bear, ‘“What’s My DNA Worth Anyway?” A
Response to the Commercialization of Individuals’
DNA’ (2004) 47 Perspectives in Biology and Medicine
273-289. 
33 Irish Council for Bioethics, Report of the Working
Group on Human Biological Material (20005) (the Irish
Report), at 62. Available at: http://www.bioethics.ie/
publications.html (last accessed 30 January 2006).
34 Lori Andrews and Dorothy Nelkin, ‘Homo Economicus:
Commercialization of Body Tissue in the Age of
Biotechnology’ (1998) 28 Hastings Center Report 30 at
31.For a contrary viewpoint see Bear, above n32 at 284-
285, where he argues that an individual’s DNA sequence
information associated with information about his or
her health status has commercial value and that pay-
ment is an obvious implication of this fact.
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Hence, although the contribution that sources
make to the research endeavour needs to be better
recognised, serious questions have to be asked
about the appropriateness of financially rewarding
sources for supply of human biological material and
also about any further commodification of human
genetic databanking and biomedical research.
Having said this, there are still good reasons why
the involvement of private companies in the devel-
opment of biomedical technology is justifiable,
principally because this is likely to be the only way
to bring products to the healthcare market. The
whole endeavour of databanking human biological
material and utilisation of that material for bio-
medical research and development is only likely to
succeed if these conflicting interests can be accom-
modated. The word trust perhaps best encapsulates
the challenge that lies ahead. Sources of biological
material are only likely to be willing to continue to
provide their material if they have trust that appro-
priate ethical safeguards are in place to protect
them. But it is increasingly being recognised that
source trust goes beyond this. Sources also need to
be assured that others are not unduly profiting
from their willing participation35 and that adequate
benefit arises out of their participation, whether
from their own perspective, or that of the societal
group to whom they belong or the public as a
whole. 
Similarly, it is likely that researchers will only con-
tinue to collect, supply, maintain and utilise data-
banked material if they have trust that they will
receive adequate and appropriate benefit, whether
this is in the form of broad scientific advancement
resulting from the research endeavour, proper
acknowledgement of their research input or more
overt forms of compensation for their intellectual
input. Private companies will only be interested in
supporting the endeavour and commercially devel-
oping research results if they have trust that these
actions are in the best interests of their sharehold-
ers. In particular, they will need some assurance
that they are able to recover their investment in
research and development, which will usually
require some guarantee of clean ownership of any
intellectual property rights arising out of the
endeavour. More generally, and perhaps even most
importantly, the broader public will only support
human genetic databanking, research and com-
mercial development if they have trust in the whole
enterprise, both from the perspective that that an
appropriate balance has been achieved between
these diverse and potentially conflicting needs to
secure benefits in one form or another and also
from the perspective that inappropriate commodifi-
cation is avoided. As Jon Merz puts it: 
there are open issues about how such ventures [like
large scale population genomic databases] should be
best structured to provide incentives for the develop-
ment of useful public resources while avoiding unjust
appropriation of public goods …36
Benefit sharing is being mooted both as an ethical-
ly appropriate means of balancing the conflicting
interests involved in genetic databanking and also
as a potential solution to the problem of loss of pub-
lic trust. 
The problem of loss of public trust
It is probably fair to say that public trust in biomed-
ical science is slowly (or even, in some areas, rapidly)
eroding.37 The last few decades have not only seen
the erosion of trust in the profession of medicine,
but also in government and science. Well-publicised
organ retention scandals in British hospitals have
added to this general malaise. The most recent
uncovering of fraud by one of the most esteemed
teams of stem cell scientists is likely to erode the
fragile layer of trust that may have been forming
around this technology. The collection of medicinal
plants from developing countries for the purpose of
drug development has led to widespread use of the
phrase biopiracy. When the same methods were use
to collect samples of blood and hair from indigenous
peoples around the world in the mid-1990s this
became known as the Vampire Project. The term heli-
copter genetics has also been coined to describe the
process whereby research teams fly in to a remote
location where a particular genetic condition may be
prevalent, take family histories, bleed local residents
and return to the host laboratory to analyse the sam-
ples, never to be seen or heard from again.38
35 A recent review of public perceptions of genetic databank-
ing found that concerns about commercialisation are
prevalent among many publics. Edna Einsiedel, Whose
Genes, Whose Safe, How Safe? Publics’ and Professionals’
Views on Biobanks (Canadian Biotechnology Advisory
Committee; 2003) at 17. Available at: http://cbac-
cccb.ic.gc.ca/epic/internet/incbac-cccb.nsf/en/
ah00511e. html (last accessed 30 January 2006).
36 Merz, above n2 at 263. See also Mark Stranger, Don
Chambers und Dianne Nicol ‘Capital, Trust and
Consultations: Databanks and Regulation in Australia’
(2006) 15 Critical Public Health 343. 
37 On this point see also Kaye and Martin, above n12 at 1146.
38 Newfoundland and Labrador Department of Health
and Community Services, Policy Implications of
Commercial Genetic Research in Newfoundland and
Labrador (January 2003) (the Newfoundland Report) at
12. Available at: www.nlcahr.mun.ca/research/
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The negative impact of such activities on public
trust is likely to be most acute where there is com-
mercial involvement. The industry sector probably
will always be viewed with some scepticism by the
public because of its perceived ‘profit at all costs’
mentality. The pharmaceutical industry, in particu-
lar, is seen as being predominantly profit driven,
even though (or perhaps because) it is developing
products to serve the public good. The increased
commercialisation of human genetic and stem cell
research is likely to further threaten public trust in
this sector, particularly if there is the perception of
conflict of interest, where profits come before
patient care or free exchange of research results.39
Graeme Laurie and Kathryn Hunter argue that  re-
presents a break down in the traditional altruistic
gift model for organising medical research.40
It seems that the problem is most acute when the
language of ownership is introduced. For example, in
2000 the Australian biotechnology company
Autogen Ltd entered into negotiations with the gov-
ernment of Tonga to set up a population database
on this small Pacific Island. The project was aban-
doned in 2002 following public opposition.
According to Geneviève Cardinal and Mylène
Deschênes, one of the reasons for the failure of the
project was concern about ‘the conversion of the
islanders DNA into corporate property through
patent monopolies’.41 The whole notion that
biobanked material can be the subject of commerce,
to be bought and sold like any other commodity is
deeply troubling for many members of society.42
Would public trust be restored simply by allowing
sources of human genetic material to enter the
world of commerce and be paid for their contribu-
tion? Is this really what we mean when we talk
about benefit sharing? Would it be better to free the
research endeavour as far as possible from the fet-
ters of commodification rather than encouraging
further proprietary claims? Would it be fair to allow
the downstream developers of new healthcare prod-
ucts to reap the benefits of the endeavour, without
having to provide a share to other participants? Is
benefit sharing the one right answer to this com-
plex web of questions? According to one recent
report, the concept of benefit sharing does not
attempt to denounce commercialisation, but it
seeks to promote the idea that those who directly
financially profit ought to contribute to the donors
of the material, without such donation amounting
to an inducement.43 Teasing out an appropriate
mechanism to achieve this end requires further
exploration.
Theoretical rationale for benefit sharing
Both from the ethical analysis outlined above and,
a matter of common sense and decency,44 there are
strong grounds for arguing that, at the very least,
researchers, databanks operators and other individ-
uals involved in genetic databanking have the fol-
lowing moral obligations:
– to sources, to properly recognise their willing
participation;
– to vulnerable members of society, to avoid coer-
cion;
– to the scientific community as a whole, to dis-
close and make available the results of research
using databanked materials; and
– to society as a whole, to ensure that the benefits
stemming from research using databanked
materials are shared by all, with particular focus
on the needs of disadvantaged groups in both
developing and developed countries.
Do any of these obligations equate with a moral
obligation to share in the financial rewards derived
from research and development utilising data-
banked human genetic material?  Ruth Chadwick
and Kàre Berg express the view that although intu-
itively, sharing of economic benefits seems morally
desirable, it is also difficult to identify any specific
reason why the pharmaceutical industry should be
obliged to share the revenue from their genomic
research.45 Indeed, Berg further argues that any
rule requiring sharing of economic benefits may be
in conflict with other rules that state that the
reports_search/DP_Final__Report.pdf (last accessed 30
January 2006); Rose, above n12 at 9.
39 Don Chalmers and Dianne Nicol ‘Commercialisation of
Biotechnology: Public Trust and Research’ (2004) 6
International Journal of Biotechnology 116
40 Graeme Laurie and Kathryn G Hunter, ‘Benefit-sharing and
Public Trust in Genetic Research’ in Gardar Árnason,
Salvör Nordal and Vilhjámur Árnason  (eds), Blood &
Data: Ethical, Legal and Social Aspects of Human
Genetic Databases (Reykjavik: University of Iceland
Press & Centre for Ethics; 2004) 323 at 323.
41 Above n10 at 61, citing B. Burton, ‘Proposed Genetic
Database on Tongans Opposed (2002) 324 British
Medical Journal 443.
42 Sheremeta, above n24 at 53. 
43 Irish Report, above n33 at 64.
44 Emerging international principles, discussed later in
this article, also add strength to this argument. 
45 Ruth Chadwick and Kàre Berg, ‘Solidarity and Equity: New
Ethical Frameworks for Genetic Databases’ (2001) 2
Nature Reviews Genetics 318.
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human body should not be a source of income.46 In
his view, the difficulty for individual sources is that
they have not done anything valuable with their bio-
logical material, and, if there is a duty to pay, the
rights of the scientists that have made the sample
valuable may exceed those of the source. He con-
cludes that: ‘specific strong arguments for financial
compensation to individuals are hard to find’ [his
emphasis].47
Others have also commented on the difficulty in
finding some underlying normative justification for
benefit sharing.48 According to Richard Gold and
Tim Caulfield, these problems arise because the
focus of the analysis remains based in property
rhetoric and the obligation to compensate for con-
tribution.49 In the alternative, they support justifi-
cations based on distributive justice, that everyone
has the right to share in scientific advances and
their benefits.50 Berg uses the language of solidari-
ty, which extends from a responsibility to make
one’s biological material available for research to
support for people in need to a duty to help the
needy or to help countries develop.51 Some policy
documents also provide support for the applicabili-
ty of both of these principles when attempting to
find justifications for benefit sharing, adding fur-
ther that recognition that the human genome is the
common heritage of humanity52 requires that bene-
fits accruing from genetic research should benefit
all the people.53
These principles provide solid justification for shar-
ing of benefits across society, but they do not pro-
vide a great deal of support for arguments that indi-
vidual sources or the groups to whom they belong
deserve to receive special benefits. In addressing
this problem, Charles Wiejer argues that what real-
ly is required is a new ethical principle, the princi-
ple of respect for communities.54 But whether ben-
efit sharing actually needs some form of normative
ethical justification is a moot point. Laurie and
Hunter sensibly bring the debate squarely back to
the issue of trust.55 They argue that, aside from
these normative principles, lack of trust of itself is
sufficient rationale for benefit sharing. In support
of this argument, they suggest that benefit shar-
ing: ‘allows the normatively appealing gift model
while redressing the palpable imbalance of power
in the researcher-subject relationship’ by providing
a ‘continuing obligation to ensure that financial
benefit (profit) to the researcher is shared in some
way with the participant or her community’ [their
emphasis].56
Accepting that there is a strong linkage between
trust and benefit sharing, and that some form of
benefit sharing is desirable both practically, to pro-
mote trust, and also (perhaps more arguably) from
the normative perspective, the difficult issues of
determining what benefits should be shared and
how they should be allocated remain. Mark
Rothstein notes that calls for benefit sharing arose
in the first place because of actual or perceived
exploitative behaviour.57 Clearly, this problem
needs to be addressed. However, he also expresses
concern about what he refers to as ‘true benefit
sharing’, which, he says, would require a restruc-
turing of the biomedical research system, technolo-
gy transfer laws, and intellectual property laws.58
Kàre Berg also raises a number of practical difficul-
ties with sharing of financial benefits. In particu-
lar, he cautions against creating a general rule that
financial compensation should be paid at the outset
because of the difficultly in predicting success and
the stultifying effect that this could have on univer-
sity research.59
The benefit sharing obligation does not necessarily
have to be restricted in this way, to focus exclusive-
46 Kàre Berg, ‘The Ethics of Benefit Sharing’ (2001) 59
Clinical Genetics 240 at 242-243.
47 Ibid at 243.
48 See, for example, E Richard Gold and Timothy A Caulfield,
‘Human Genetic Inventions, Patenting and Human
Rights (Justice Canada; 2003) at 45-46. Available at:
http://www.cipp.mcgill.ca/db/published/00000006.
pdf (last accessed 30 January 2006). 
49 Ibid. See also Kadri Simm, ‘Benefit-sharing: an Inquiry
regarding the Meaning and Limits of the Concept in
Human Genetic Research’ (2005) 1/2 Genomics, Society
and Policy 29.
50 Gold and Caulfield, above n48 at 47.
51 Berg, above n46 at 242.
52 Note that UNESCO’s Universal Declaration on the
Human Genome and Human Rights (adopted on the
report of Commission III at the 26th plenary meeting,
11 November 1997) refers in Article 1 to the human
genome as being, in a symbolic sense the heritage of
humanity.
53 Irish Report, above n33 at 63.
54 Charles Weijer, ‘Benefit-sharing and Other Protections
for Communities in Genetic Research’ (2000) 58
Clinical Genetics 367 at 368.
55 Above n40 at 325.
56 Ibid.
57 Mark A Rothstein, ‘Expanding the Ethical Analysis of
Biobanks’ (2005) 33 The Journal of Law, Medicine &
Ethics 89 at 97.
58 Ibid at 96.
59 Berg, above n46 at 241-242
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ly on direct financial benefits. The umbrella of ben-
efit sharing could also include more indirect bene-
fits, such as preferential access to new healthcare
developments, as well as genuine efforts to fully
disclose all relevant information, particularly infor-
mation about the process of commercialisation, and
to explicitly recognise the input that sources have
made. It could be argued that the promise of new
healthcare developments is sufficient to satisfy any
obligation to provide benefits to participants in bio-
medical research. However, for Laurie and Hunter,
such abstract promises, that are only likely to bene-
fit future generations, are not enough.60 It is
argued here that if benefit sharing is a desirable end
in this area of human genetic databanks then it
must be addressed in a genuine way. If researchers
and databank operators try to satisfy obligations to
provide for benefit sharing by means of trite state-
ments of future possibilities, then rather than pro-
moting trust, they could further erode it. This is
not to say that the only benefit that should be con-
sidered is financial benefit. 
Emerging international principles
A number of international principles provide some
guidance in clarifying the concept of benefit shar-
ing and the obligations that it might entail in the
area of human genetic databanking.61 Some guid-
ance can be obtained from the Convention on Biological
Diversity (the CBD) and associated guidelines in rela-
tion to access to non-human genetic resources.62
Article 15.7 of the CBD calls for fair and equitable
sharing of the results of research and development
and the benefits arising from the commercial and
other utilization of genetic resources. It is impor-
tant to note that the CBD and associated guidelines
only apply to non-human genetic resources.
However, it has been argued that they, neverthe-
less, provide a rational starting point in determin-
ing how benefit sharing could apply in the context
of human genetic material.63 The International Treaty
on Plant Genetic Resources for Food and Agriculture, adopted
by the Food and Agriculture Organisation in
November 2001, also has similar provisions. The
Treaty’s objectives are the conservation and sus-
tainable use of plant genetic resources for food and
agriculture and the fair and equitable sharing of
benefits derived from their use, in harmony with
the CBD, for sustainable agriculture and food secu-
rity.
Although the benefit sharing provisions in these
instruments have caused concern in some quarters,
they do make good common sense. Kàre Berg has
commented that there would be an almost univer-
sal feeling that it would be unfair to take natural
resources to make marketable products without giv-
ing something back.64 He argues that the same is
true where research on genes in a family leads to
marketable products and revenues for the pharma-
ceutical industry and the family is given nothing
back.65 Yet there is much less support in interna-
tional law for benefit sharing in respect of human
genetic material. 
UNESCO’s International Declaration on Human Genetic
Data66 is perhaps the most influential normative
statement on benefit sharing in relation to biomed-
ical research. It provides that: 
benefits resulting from the use of human genetic data,
human proteomic data or biological samples collected
for medical and scientific research should be shared
with the society as a whole and the international com-
munity.67
Notably, it adds that special assistance may be pro-
vided to the persons and groups that have taken
part in the research.68 The Declaration goes on to
provide some further clarification of the forms that
benefit sharing may take,69 but does not provide
any further specific guidance as to the nature of the
special assistance mentioned above. UNESCO’s ear-
lier Universal Declaration on the Human Genome and Human
Rights also emphasises the importance of interna-
tional collaboration and free exchange of knowl-
edge,70 but is silent on benefit sharing as such. 
The Human Genome Organisation (HUGO) Ethics
Committee’s Statement on Benefit Sharing provides
60 Laurie and Hunter, above n40 at 325.
61 For a helpful summary see Bartha Maria Knoppers,
‘Biobanking: International Norms’ (2005) 33 The
Journal of Law, Medicine & Ethics 7. 
62 Bonn Guidelines on Access to Genetic Resources and
Fair and Equitable Sharing of the Benefits Arising out
of their Utilisation (Decision VI/4 from the sixth meet-
ing of the Conference of the Parties to the Convention
on Biological Diversity in 2002)
63 Bartha Maria Knoppers and Lorraine Sheremeta, ‘Beyond the
Rhetoric: Population Genetics and Benefit-sharing’
(2003) 11 Health Law Journal  89.
64 Berg, above n46 at 240.
65 Ibid.
66 UNESCO, International Declaration on Human Genetic
Data. Adopted on 16 October 2003 by the 32nd session
of the General Conference of UNESCO.
67 Ibid Article 19(a).
68 Ibid Article 19(a)(i).
69 Ibid Article 19(a)(ii)-(vii).
70 See particularly Articles 12 and 18.
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more explicit guidance on the appropriateness of
benefit sharing and the obligations it entails, both
from the broad societal perspective and the more
specific perspective of the source and/or their social
group.71 The statement recommends that:
– all humanity should share in, and have access
to, the benefits of genetic research;
– benefits should not be limited to those individu-
als who participated in such research;
– there should be prior discussion with groups or
communities on the issue of benefit-sharing;
– even in the absence of profits, immediate health
benefits as determined by community needs
could be provided;
– at a minimum, all research participants should
receive information about general research out-
comes and an indication of appreciation; and
– profit-making entities should dedicate a per-
centage (e.g. 1% - 3%) of their annual net profit to
healthcare infrastructure and/or to humanitari-
an efforts.
The first five dot points encapsulate some of the key
concerns that have been raised earlier in this arti-
cle. The last dot point is more controversial. It clear-
ly puts the issue of financial benefit sharing onto
the agenda, and it avoids the problem of coercion by
recommending that profits should be dedicated to
healthcare infrastructure or other humanitarian
needs. However, on the one hand, this may not pro-
vide adequate specific benefit to the source or to
their social group and on the other hand, the oblig-
ation to provide a fixed percentage irrespective of
the actual success of the product may be seen as too
significant an impost for some commercial entities. 
The Statement does provide some further clarifica-
tion that benefit means more than financial bene-
fit. It defines benefit as:
a good that contributes to the well-being of an individ-
ual and/or a given community (e.g. by region, tribe,
disease-group...). Benefits transcend avoidance of
harm (non-maleficence) in so far as they promote the
welfare of an individual and/or of a community. Thus,
a benefit is not identical with profit in the monetary or
economic sense. Determining a benefit depends on
needs, values, priorities and cultural expectations.
There is support in the academic literature for
including in this broad definition of benefit sharing
such scientific benefits as: prompt diffusion of
research results, collaboration with members of the
scientific community and attribution of licences for
patented inventions; and such general and specific
social benefits as: access to future treatments
resulting from the research, donation of part of the
profits to a local humanitarian organisation and
financial support for research or contribution to
health technology infrastructures.72
There are some international instruments that pro-
vide further specific guidance on benefit sharing in
relation to human genetic databanking. As with the
more generalist instruments, there are two aspects
that need to be balanced. One aspect focuses on the
need to share benefits amongst the community as a
whole, rather than at the level of the particular
individual or the group. Indeed, there is a growing
trend to describe databanks as global public goods
rather than as collections of individual pieces of
property.73 UNESCO’s Statement on Human Genomic
Databases describes databanks in this way, and in
recommendation 3 it states that the free flow of
data and the fair and equitable distribution of ben-
efits from research using databases should be
encouraged. At the same time, Recommendation 6
recognises that researchers, institutions and com-
mercial entities have a right to a fair return for
their intellectual and financial contributions.
There is also some support at the international level
for the more specific aspect of benefit sharing at the
level of the individual or group. The World Health
Organisation (WHO), for example, emphasises
that, in recognising the potential value of human
material and human genetic information, it is also
necessary to recognise the inherent value of the per-
son from whom the material or information is
derived. 74 Hence, it suggests that, in exchange for
the supply of materials, there should be an under-
taking that some kind of benefit will ultimately be
returned, either to the individual from whom the
material is taken or the general class of people to
whom the individual belongs. The stated rationale
for this conclusion is that intellectual property
71 Human Genome Organisation Ethics Committee
(2000) Statement on Benefit Sharing, Available
at:http://www.hugo-international.org/Statement_
on_Benefit_Sharing.htm (last accessed 30 January
2006).
72 Cardinal and Deschênes, above n10 at 60. See also Mylène
Deschênes, Geneviève Cardinal, Batha Maria Knoppers and
Katherine C Glass, ‘Human Genetic Research, DNA
Banking and Consent, a Question of Form?’ (2001) 59
Clinical Genetics 221 at 229.
73 See Knoppers, above n61 at 11.
74 World Health Organization’s European Partnership on
Patients’ Rights and Citizens’ Empowerment, Genetic
Databases: Assessing the Benefits and the Impact on
Human & Patient Rights (2003) available at http://
www.law.ed.ac.uk/ahrb/publications/online/whofi-
nalreport.pdf (last accessed 10 January 2005).
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rights in the products of research do not ‘accord an
unfettered reign to the rights holder to do what
they wish with the property’, but rather an obliga-
tion to seek a more equitable equilibrium in the rel-
ative weighting of interests.75
In summary, these instruments provide support for
both general and specific benefit sharing. They also
provide some clarification as the nature of the ben-
efit sharing obligation. It seems that it is difficult to
divorce benefit sharing entirely from the financial
realm. Having said this, there is more to it than a
simple requirement to return a fixed percentage of
profits. Clearly then, the actual content of the
obligation still needs further elucidation. It is
equally necessary to move beyond the principles
and consider how the obligation actually arises and
can be enforced in practice.
Existing domestic ethical and legal benefit
sharing obligations
Although the number of international instruments
that raise the issue of benefit sharing is growing,
the same cannot be said domestically, at least in the
industrialised countries that are actively promoting
the development of a medical biotechnology indus-
try.76 In many of these countries, ethical guidelines
provide no absolute obligation to inform research
participants about the acquisition of intellectual
property rights or about arrangements for commer-
cial development of research findings.77 Even more
clearly, there is no obligation to return any of the
profits of commercialisation to participants,
because of the widely held view that offering finan-
cial inducement for participation in research is
unethical.78 A number of policy documents from
around the world that have focused specifically on
the appropriate regulation of human genetic data-
banks have consistently recommended that sources
should not receive financial reward for providing
their material for databanking and that they should
be informed of this when asked for their consent.79
They do, at least, recommend that when sources are
asked to consent to collection storage and utilisa-
tion of their material they should be informed of
any commercial objectives or likely outcomes of
research using their material as part of the process
of obtaining fully informed consent.80 But they pro-
vide little guidance as to whether or not there are
any benefit sharing obligations and, if such obliga-
tions do arise, what their content might be.
Similarly, although a number of domestic laws
impose rights and duties in relation to the commer-
cialisation of the results of databank research, none
of these provides a great deal of assistance in deter-
mining whether there are any legally enforceable
benefit sharing obligations.81 For example, patent
law provides for temporary monopolies for inven-
tions that satisfy the requirements of novelty,
inventive step and industrial applicability and that
are fully disclosed. Cell lines and genes are consid-
ered to be capable of fulfilling these requirements
in many jurisdictions, provided that they are in
some way isolated from their natural environ-
ment.82 Patents are made available to inventors,
which might include the researchers who carry out
projects using banked materials and perhaps the
bankers themselves. However, there is no room in
this definition to include the sources of the raw
materials from which inventions are derived.
Moreover, there is no requirement in patent law to
inquire into the ethical appropriateness of research
that leads to patentable inventions. The interna-
tional Agreement on Trade-related Aspects of
Intellectual Property lists the matters that mem-
bers of the World Trade Organisation are allowed to
exclude in their domestic patent legislation. The
only exclusion that may be relevant is for inven-
tions, the commercial exploitation of which would
be contrary to pubic order or morality.83 It is diffi-
cult to see how this exclusion would allow for
inquiry into the research that precedes the invention. 
The law on ownership of human tissue and human
genetic information is less emphatic on the absence
of benefit sharing obligations, but nevertheless
appears to be similarly unhelpful. The widely
75 Ibid. 
76 Particularly focusing on North America, Europe, Japan
and Australia.
77 For further details see: Dianne Nicol, Margaret Otlowski and
Don Chalmers ‘Consent Commercialisa-tion and Benefit
Sharing’ (2001) 9 Journal of Law and Medicine 80
78 Ibid.
79 For example, see the Irish Report, above n33, Recom-
mendation 12 
80 See, for example, the Irish Report, above n33,
Recommendation 13; Medical Research Council,
Human Tissue and Biological Samples for Use in
Research: Operational and Ethical Guidelines (2001).
See also Lori B. Andrews, ‘Harnessing the Benefits of
Biobanks’ (2005) 33 The Journal of Law, Medicine and
Ethics 22, particularly at 26.
81 See further on this point: Nicol et al, above n77; Dianne
Nicol ‘Property in Human Tissue and the Right of
Commercialisation: the Interface between Tangible
and Intellectual Property’ (2004) 30 Monash University
Law Review 139
82 See Dianne Nicol, ‘On the Legality of Gene Patenting’
(2005) 29 Melbourne University Law Review 1.
83 In Article 27.2.
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accepted position is that both unprocessed human
tissue and the human genome itself are not gener-
ally capable of ownership and there is little or no
authority for a successful claim by a source to legal
ownership (or interest) in any commercial product
derived from their tissue.84 The commercial prod-
uct is generally seen as severed where there is an
intervening and independent creative dealing with
the material. However, from time to time there
have been calls for recognition of sources’ property
rights in their biological materials. It is argued that
this would facilitate ongoing control by sources of
the material they provide and give them an entitle-
ment to share in the profits arising out of commer-
cial use of their material.85 In effect, sources would
be provided with inalienable property rights that can-
not be waived or assigned to the director of the
repository or other interested parties.86 However,
this concept of inalienability has been criticised
because, although it would provide for ongoing con-
trol, it would inhibit profit sharing and could actu-
ally add confusion to the legal status of human bio-
logical material, rather than clarify it.87 It is salu-
tary to note that in Australia, a comprehensive
report by the Australian Law Reform Commission
and Australian Health Ethics Committee on the
protection of genetic information recommended
against the recognition of property rights in human
biological material for various reasons.88
Equity may intervene if there is breach of a fiducia-
ry obligation, for example.89 However, even if a
researcher or a databank manager were found to
owe a fiduciary obligation to sources of biological
material, it is most unlikely that such an obligation
would extend to the downstream developers of com-
mercial products, even if development of the prod-
ucts was directly linked to that particular material.
Contract law could also have a role to play, particu-
larly where benefit sharing arrangements have
been specifically negotiated and agreed to.90
However, absent a legally enforceable contract with
express benefit sharing terms, it is unlikely that
contract law could provide much assistance. Even if
the normal consent arrangement between the
source of human biological material and the
researcher or databank manager could be seen as
contractual in nature, it is unlikely that benefit
sharing terms would be implied. In any case, con-
cern has been expressed about the propriety of
using contract law to solve such future ethical
dilemmas.91
In summary, then, there is a lack of certainty in the
extent to which relevant domestic laws could be
used to impose benefit sharing obligations on data-
bank managers, researchers and downstream users
without more precision as to the nature of obliga-
tions. Despite the absence of clear legal obligations
or ethical guidelines, it is argued here that the
funding agencies, databank operators and
researchers themselves have an ethical obligation
to set their own standards providing for benefit
sharing, with the assistance of adequate and appro-
priate policy documents. It is also sensible from the
practical point of view to do so, to promote trust in
their endeavours. 
Human genetic databank policies
As the number and diversity of databanks bur-
geons, so too does the number and diversity of data-
bank policies. Whilst consolidated facilities like the
ATCC and the more informal networks are provid-
ing a greater degree of uniformity in these policies,
a number of databanks still either lack formal poli-
cies or do not make their policies readily available.
In this section, the key features of some of these
policies are discussed, particularly as they relate to
access, intellectual property and benefit sharing. 
A study commissioned by the National Cancer
Institute National Dialogue on Cancer provides an
insight into how intellectual property and access
issues are dealt with in human genetic databanks
84 On this point see generally Nicol, above n81.
85 See further on this point Graeme Laurie, Genetic Privacy:
a Challenge to Medico-legal Norms (2002) at 318.
86 Ibid.
87 Jasper A Bovenberg, ‘The New Case for an Inalienable
Property Right in Human Biological Material:
Empowerment of Sample Donors or a Recipe for a
Tragic Anti-common?’ (2004) 1:4 SCRIPT-ed. 
88 Australian Law Reform Commission and Australian
Health Ethics Committee Report 96 Essentially Yours.
The Protection of Human Genetic Information in
Australia (Canberra: Commonwealth of Australia;
2003) at 530-535 and Recommendation 20-1.
89 This was the outcome of the well-known litigation in
Moore v Regents of the University of California 51 Cal.
3d 120 (Cal. 1990).
90 There is one example of a patient group (PXE
International) participating in research relating to the
genetic disorder pseudoxanthoma elasticum (PXE)
negotiating a contractual arrangement with resear-
chers giving the group a share in the rights to a patent
application filed by the researchers. See Donna M.
Gittner, ‘Ownership of Human Tissue: a Proposal for
Federal Recognition of Human Research Participants’
Property Rights in Their Biological Material’ (2004) 61
Washington and Lee Law Review 257 at 315-325.
91 Larry L Palmer, ‘Should Liability Play a Role in Social
Control of Biobanks?’ (2005) 33 The Journal of Law,
Medicine and Ethics 70 at 76.
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focusing on cancer research in the US. In 2002-2003,
researchers at the RAND Corporation conducted a
series of case studies on twelve tissue repositories in
the US on behalf of the National Cancer Institute.
The purpose of the study was to assess the useful-
ness of these repositories in genomics- and pro-
teomics-based cancer research and to identify ‘best
practice’.92 The final report discusses best practice
in a range of areas, including privacy, ethics and
law as well as public relations and marketing. For
the present purposes, Chapter 8 on Intellectual
Property and Legal Issues is the most relevant. 
The report gives an indication of the core features
that should be included in arrangements for access
to deposited materials, which include the follow-
ing: 
– use should only be for the purpose specified in
the application for access; 
– no attempt should be made to obtain identifying
information; 
– there should be no transfer to third parties with-
out prior written permission of the repository;
and
– any publication resulting from use of the mate-
rials should acknowledge the repository. 
These requirements are likely to fulfil the obliga-
tion to provide a basic level of protection to sources
of deposited material. However, disappointingly,
there is nothing in these requirements that speci-
fies that the contribution of the source should be
recognised in any way.
Despite a finding that it is best practice to have an
intellectual property policy, not all of the reposito-
ries surveyed actually had one.93 Nevertheless,
some general trends regarding handling of intellec-
tual property issues do emerge from the survey. It
was found that most repositories do not retain any
rights to downstream intellectual property pro-
duced using the material they distribute, unless
they are undertaking collaborative research, in
which case the intellectual property may be jointly
owned.94 As a general rule, the institution or
organisation where the research is conducted
claims ownership of the intellectual property
rights. 
The National Cancer Institute report further con-
cludes that it is also best practice to require a mate-
rial transfer agreement (MTA) to be executed in
accordance with the same terms as the best practice
intellectual property policy. This is important,
because it gives contractual force to the terms of the
intellectual property policy included in the MTA.
However, the report provides no evidence of the
inclusion of any benefit sharing obligations in the
intellectual property policies or MTAs. Although it
is generally specified that individuals who con-
tribute material have the right of withdrawal
unless stripped of identifiers, they generally have
no other rights, including no right to compensation
for their participation.
The UK Biobank draft Policy on Intellectual Property and
Access is cast in somewhat similar terms.95 It has the
usual provision that intellectual property arising
out of research using the resource vests in the inves-
tigator creating it. However, its access policy is
somewhat unusual in that it provides that, as a gen-
eral rule, researchers will not be provided with
access to stored tissue. Instead, analysis will be
undertaken by Biobank or a laboratory contracted
by it. An access agreement has to be entered into,
and an access fee has to be paid, although fees for
non-commercial research are nominal. Where tis-
sue is provided, a standard form MTA is required to
be executed. 
The standard ATCC MTA96 provides the signatory
with permission to make and use material, repli-
cates and derivatives for research purposes in the
signatory’s own laboratory only. No permission is
given to distribute, sell or otherwise transfer the
provided material or replicates or derivatives.
Commercial use is prohibited without authorisa-
tion. ATCC and/or its contributors retain ownership
of the material, replicates and derivatives (but pre-
sumably not the intellectual property that is creat-
ed from their use).
Organisations that make their collections available
through the ATCC may require a separate MTA to be
92 Elisa Eiseman, Gabrielle Bloom, Jennifer Brower, Noreen Clancy
and Stuart S Olmsted, Case Studies of Existing Human
Tissue Repositories: “Best Practices” for a Biospecimen
Resource for the Genomic and Proteomic Era prepared
for the National Cancer Institute National Dialogue on
Cancer (Arlington VA: Rand Science and Technology;
2003). Available at: http://www.rand.org/pubs/
monographs/MG120/ (last accessed 30 January 2006).
93 Ibid at 140.
94 Ibid at 138.
95 As at 11 January 2005. Available at: http://www.
ukbiobank.ac.uk/ethics/IPandAccess.php (last
accessed 27 January 2006).
96 Available at: http://www.atcc.org/documents/mta/
mta. cfm (last accessed 27 January 2006).
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executed. For example, the Johns Hopkins Univer-
sity requires the execution of a Non-exclusive
License Agreement for distribution to a commercial
entity. The only major difference from the ATCC
MTA is that it is explicitly stated that the material
cannot be used for work on human subjects, includ-
ing diagnostic testing. The Wistar Institute also
requires a special MTA for some of its cell lines, and
in this case the issue of intellectual property owner-
ship is more explicitly provided for. In addition to
the usual terms, it specifies in clause 4(b) that if the
research use results in an invention, the Wistar
must be notified promptly and confidentially,
whereupon inventorship is to be determined in
accordance with patent law (if patentable) or other-
wise by mutual agreement and that the parties will
cooperate regarding protection and disposition of
all jointly owned intellectual property. Some
Australian organisations have taken up this clause
in their MTAs.97
These MTAs and intellectual property policies allow
databank operators to retain some control over the
material that they provide access to. Restrictions on
transfer to third parties are particularly important
in deterring inappropriate use of accessed material.
In some circumstances, the databank operators will
be able to claim a share of intellectual property gen-
erated through use of the material. Whilst disputes
about contribution and ownership will inevitably
arise, it is probably fair to say that, as a general
rule, where intellectual property and access policies
of this nature are in place they are likely to provide
an acceptable level of clarity to promote trust by the
relevant parties (databank operators, researchers
and commercial developers). However, there is a
marked absence of any requirement whatsoever to
provide for any other form of benefit sharing,
whether in the broad sense of sharing with society
or in the specific sense of sharing with the source
and/or their social group.
The operators of databases of human genetic infor-
mation tend to be more explicit in providing for
broad social benefits. The primary way that this
form of benefit sharing is secured is by making the
data available rapidly and without restriction. For
example, the entirety of information relating to the
HapMap Project is in the public domain. In the
early stage of the project it was felt necessary to
impose restrictions on the use of data. In order to
register for access to the online database partici-
pants were required to accept the terms of the
licence on the click of a button.98 Without going
into details about the scientific rationale for this, it
was felt necessary because it was possible for users
to capture early stage data and take out patents,
thereby potentially restricting access for other
users. The licence required users to undertake that
they would not restrict others from accessing or
using the data produced by the project. This obliga-
tion was no longer required once further data had
been placed in the public domain, which occurred
about 15 months into the project.
In addition to the scientific benefits likely to arise
out of rapid release of information, participants in
the HapMap Project claim that it offers the follow-
ing benefits to society: 
it is hoped that the HapMap Project will eventually ben-
efit the health of all people. Most of the benefits, how-
ever, will not be immediately apparent, and some
might take years to materialize. So, in the short term,
the main beneficiaries will not be sample donors, their
families or their communities, but researchers, who
will gain professional rewards, and companies, that
will be able to develop drugs, diagnostic tests or other
commercial products from research using the
HapMap.99
Commentators like Laurie and Hunter would doubt-
less object to this statement on the basis that the
benefit is too abstract in nature, and does not ade-
quately recognise the input of sources of the origi-
nal material. However, in circumstances such as
this, where the material that is being provided by
the databank is DNA sequence information that is
essentially generic and where there are likely to be
many steps between the original sequencing and
97 One example is the Kathleen Cunningham Foundation
Consortium for Research into Familial Breast Cancer,
also known as kConFab. Its Transfer of Materials
Agreement gives the repository the right to vet publi-
cations, to be recognised as an author and to identify
potentially patentable technology. It also specifies that
inventorship is to be determined in accordance with
Australian patent law (if patentable) or otherwise by
mutual agreement and that the parties will negotiate
an agreement regarding any jointly owned intellectual
property specifying sharing of income, patent costs
and the administration of any patents. Available at:
http://www.kconfab.org/documents/kconfabMTA.pd
f (last accessed 30 January 2006).
98 Available at: http://www.hapmap.org/cgi-perl/regis-
tration (last accessed 1 February 2006). See also Chokshi
and Kwiatkowski, above n20 at 8. Free access to data is a
common feature of all large scale international public
sequencing projects. See: The Wellcome Trust, Sharing
Data from Large-scale Biological Research Projects: a
System of Tripartite Respon-sibility, Report of a meet-
ing organised by the Wellcome Trust and held on 14-15
January 2003 at Fort Lauderdale, USA. Available at:
http://www.wellcome.ac.uk/doc_wtd003208.html
(last accessed 26 January 2006).
99 International HapMap Consortium, above n21 at 473.
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product development, the benefit of free exchange
of information together with a general promise of
future benefit is probably sufficient. But the situa-
tion is quite different for the UK Biobank and like
projects, where each individual source is expected
to make their tissue available for research via the
databank, together with other information. In such
circumstances serious questions have to be asked as
to whether research and the mere promise of future
healthcare benefits is sufficient. Yet this is precise-
ly what the UK Biobank intellectual property and
access policy offers in its core principles of intellec-
tual property and access.100 The policy goes even
further than this, expressly providing that, a gen-
eral rule, there is no requirement to return a share
of any profits generated using the Biobank resource
to Biobank.101
There is very little evidence of any explicit require-
ment for specific benefit sharing with sources or
their social groups in the vast majority of databank-
ing policies throughout the world. On the contrary,
some policies take great care to ensure that sources
know they are not entitled to any financial benefit
from their contribution to the research effort but
are curiously silent on other forms of benefit. One
such example is the Biorepository Protocols of the
Australasian Biospecimen Network, which simply
state in the section of the Protocols dealing with
ethical issues associated with use of human
biospecimens (or human biological material, using
the terminology used elsewhere in this article) that
the following information should be provided to
sources on commercial issues:
Our research is mostly directed to improving under-
standing of disease. Sometimes the research will lead to
findings that result in the development of a commercial
test or treatment that may be overseen by pharmaceuti-
cal companies. Australian law indicates that there is no
financial reward or payment to you in such an event.102
There is no mention in the guidelines of any require-
ment to explain whether any financial or other ben-
efit accrues to the biorepository as a result of the
development of a commercial test or treatment, or
whether there is any other form of benefit to the
source, or any broader public benefit.
In contrast, the Quebec Network of Applied Genetic
Medicine is much more explicit on the need to pro-
vide for benefit sharing arrangements in its pro-
posed Statement of Principles on the Ethical Conduct of
Research Involving Populations, which takes up a num-
ber of the recommendations in from the HUGO
Statement on Benefit Sharing. It provides, in clause 7 on
commercialisation, that:
The eventual sharing of any benefits with the popula-
tion should be discussed at the outset. This sharing
could take different forms such as: an access to medical
care, to future treatments or drugs developed; a contri-
bution of a portion of the benefits to a humanitarian
organization; support for local needs, or support for
technological infrastructures or health services to the
population, etc.103
This clause goes on to address the need for freedom
of research, which it says should be promoted by
respecting the principle of public access and man-
agement of the potential for conflict of interest to
arise from the commercialisation process. As with
the HUGO Statement, this clause encapsulates
many of the key concerns highlighted earlier and it
could provide a model for other databanking policy
statements. Admittedly, the policy is cast in fairly
broad terms and does not provide specific details as
to how benefit sharing should actually be provided
for.104 But this may well turn out to be the most
sensible option. It has been recognised elsewhere
that a ‘one size fits all’ model is not appropriate and
that benefit sharing policies can only provide gen-
eral guidance.105 By inviting discussions about ben-
efit sharing at the outset, the policy encourages the
parties to consider the social group’s particular
needs and cultural values.
A report by the Newfoundland and Labrador
Department of Health and Community Services
raises similar considerations, but recommends that
the province should play a central role in negotiat-
ing benefit sharing arrangements, which, it fur-
ther recommends, should be required for any
human genetic research with commercial poten-
tial.106 These arrangements might include free
access to genetic tests for all residents of the
province, for example.107 Some of the reasons put
forward to justify the proposal are: that health care
is a common good and a community held responsi-
100 UK Biobank, Draft Policy on Intellectual Property and
Access clause 5.1.
101 Ibid clause 8.3.
102 Australasian Biospecimen Network Biorepository
Protocols (October 2005) available at: http://www.
abrn.net/protocols.htm (last accessed 27 January
2006).
103 Available at: http://www.rmga.qc.ca/en/index.htm
(last accessed 26 January 2006).
104 For example, it avoids the controversial requirement
in the HUGO Statement on Benefit Sharing to return
a fixed percentage of profits.
105 Newfoundland Report, above n38 at 52
106 Ibid at iv.
107 For further examples, see ibid at 52-55.
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bility; that residents of Newfoundland and
Labrador collectively share the burdens and benefits
of individual genetic predispositions; and that
human DNA is a communal resource.108
Whilst arrangements of this nature may be diffi-
cult to implement for the larger scale databanking
project, they do present an interesting way of set-
ting up the administrative framework for negotiat-
ing and enforcing benefit sharing obligations. It is
likely that various other models of benefit sharing
frameworks will emerge once the need to address
this issue is more widely recognised.
Conclusion
There appears to be a growing realisation that
research using databanked materials will be facilitat-
ed by clear intellectual property and access guide-
lines. However, the same cannot be said with regard
to benefit sharing. There is scant evidence that this
important issue is being taken seriously. 
Bartha Knoppers and Lori Sheremeta have suggested
that it is time to go beyond the rhetoric of benefit
sharing and implement practical benefit sharing
measures.109 However, there is an even greater diffi-
culty – for the most part, the people providing the
rhetoric are not those who are most directly involved
in databanking. Until policy makers, operators,
researchers and commercial developers become
engaged in discussions about benefit sharing, the
rhetoric is empty. The theorists have presented con-
vincing arguments as to why both general and spe-
cific benefit sharing are desirable ends, particularly
from the perspective of maintaining trust. Now is
the time for all parties engaged in databanking to
seriously consider how to implement appropriate
benefit sharing mechanisms. They should not see
benefit sharing as a threat to the commercial success
of the endeavour but as an important component in
its success. As Sheremeta has put it:
… benefit sharing should be considered as a mechanism
(or rather a spectrum of mechanisms) to balance the
commercial interests with those of research partici-
pants in a way that is both respectful and reflective of
the relative contributions to the research endeavour.110
It is also important to recognise that benefit shar-
ing does not equate with paying research partici-
pants for their involvement. Nor does it equate with
commodification of human tissue. But it does
recognise the important contribution that partici-
pants, their social groupings and the public at large
make to the research endeavour. For this reason,
benefit sharing should be a mandatory considera-
tion in human genetic databanking. Provided that
all players in the databanking arena are involved in
formulating best practice guidelines for benefit
sharing policies and that benefit sharing arrange-
ments are handled with sensitivity and transparen-
cy, there can be little doubt that public trust in the
endeavour will be enhanced.
108 See generally ibid at 29-34.
109 Above n63.
110 Above, n24 at 55.
